# Hour 14: 14:00-14:59 - Sustained Afternoon High Volume

Released on 23 March 2026 | CEO Kevin Kawchak | ChemicalQDevice

## Hour Summary

Hour 14 sustains the high-volume afternoon period with 9 new patient arrivals
(PAT-ODMND-0107 through PAT-ODMND-0115), bringing concurrent patient count to
approximately 20. This hour spans the full breadth of the Physical AI robot
fleet, with procedures involving RT motion-tracking, cobot biopsy, RT
positioning for glioblastoma, pediatric companion therapy, combined imaging
and steerable needle ablation, needle placement for a parotid tumor, humanoid
rehabilitation support, diagnostic imaging, and exoskeleton rehabilitation.
Two investigational drug administrations occur under IND protocols. Robot
utilization reaches approximately 52%, reflecting sustained clinical demand.
PAT-ODMND-0097 continues an ongoing surgical procedure begun at approximately
13:20. No adverse events occurred.

## Site Status at 14:00

- Total patients on-site: approximately 20 (11 carryover, 9 new arrivals)
- Active procedures: 6 concurrent (peak)
- Robots in active mode: 15 (across hour)
- Robots in standby mode: 14
- Robots in maintenance: 0
- Queue length: 0 across all stations
- Site safety officer on duty: SSO-D2 (day shift 2)

## New Patient Arrivals

| Patient ID | Time | Age | Sex | Cancer Type | Stage | ECOG | Robot Assigned |
|-----------|------|-----|-----|-------------|-------|------|----------------|
| PAT-ODMND-0107 | 14:03 | 53 | M | NSCLC adenocarcinoma | IIB | 1 | TRACK-02 |
| PAT-ODMND-0108 | 14:08 | 37 | F | Forearm sarcoma | II | 0 | COBOT-04 |
| PAT-ODMND-0109 | 14:14 | 74 | M | Glioblastoma | IV | 2 | RTPOS-02 |
| PAT-ODMND-0110 | 14:18 | 7 | M | Pediatric AML | - | 1 | COMPN-03 |
| PAT-ODMND-0111 | 14:24 | 62 | F | HCC | III | 1 | IMAGE-04, STEER-01 |
| PAT-ODMND-0112 | 14:30 | 46 | M | Parotid tumor | I | 0 | NEEDLE-01 |
| PAT-ODMND-0113 | 14:36 | 13 | F | Pediatric osteosarcoma | - | 1 | HUMAN-01 |
| PAT-ODMND-0114 | 14:42 | 68 | M | Liver metastases | IV | 2 | IMAGE-01 |
| PAT-ODMND-0115 | 14:50 | 71 | F | Femur osteosarcoma | - | 2 | REHAB-01 |

## Active Procedures This Hour

### RT Motion-Tracking Session (14:10-14:28)
- Patient: PAT-ODMND-0107
- Robot: TRACK-02 (RT Motion-Tracking, Instance 2)
- Vault: Radiotherapy Vault 2
- Procedure: Fraction 8 of 33, 2 Gy delivery to right lower lobe lesion
- Duration: 18 minutes (calibration 2 min, treatment 14 min, exit 2 min)
- Beam gating efficiency: 93.8%
- Breathing amplitude: 3.9 mm (within 2-3 mm tolerance after coaching)
- Marker displacement: 1.7 mm average
- Treatment interruptions: 0
- Outcome: Successful completion. Full dose delivered.

Minute-by-minute summary (active procedure):
- 14:10 - Patient positioned on couch, marker block placed on chest
- 14:11 - Calibration complete, breathing pattern established at 15 BPM
- 14:12 - Beam-on, first field. Gating active.
- 14:16 - Field 1 complete (1.0 Gy delivered)
- 14:17 - Gantry rotation to field 2
- 14:18 - Beam-on, second field
- 14:22 - Field 2 complete (0.6 Gy delivered)
- 14:23 - Gantry rotation to field 3
- 14:24 - Beam-on, third field
- 14:26 - Field 3 complete (0.4 Gy delivered). Total: 2.0 Gy.
- 14:27 - Marker block removed, patient assisted to seated position
- 14:28 - Patient exits vault. Procedure complete.

### Cobot Biopsy (14:15-14:32)
- Patient: PAT-ODMND-0108
- Robot: COBOT-04 (Cobot, Instance 4)
- Station: Biopsy Station 4
- Procedure: Core needle biopsy of left forearm soft-tissue mass
- Duration: 17 minutes (prep 3 min, biopsy 10 min, hemostasis 4 min)
- Needle insertion force: 2.4 N (within 1-4 N range)
- Biopsy cores obtained: 4 of 4 planned
- Sample quality: Grade A (adequate for histopathology and molecular profiling)
- Bleeding: Minimal, controlled with direct pressure
- Outcome: Successful. Samples sent to pathology.

### RT Positioning - Glioblastoma (14:22-14:52)
- Patient: PAT-ODMND-0109
- Robot: RTPOS-02 (RT Positioning, Instance 2)
- Vault: Radiotherapy Vault 2 (after TRACK-02 cleaning cycle)
- Procedure: Stereotactic RT fraction 3 of 30, 2 Gy to left temporal GBM
- Duration: 30 minutes (mask fitting 5 min, CBCT 5 min, treatment 16 min,
  exit 4 min)
- Thermoplastic mask fit: verified, deviation less than 1.0 mm
- CBCT-to-plan registration: 0.6 mm translational, 0.3 degrees rotational
- Bevacizumab 10 mg/kg administered IV at 14:20 per IND protocol (pre-RT)
- Treatment interruptions: 0
- Outcome: Successful. Fraction delivered with high positional accuracy.

### Companion Robot Session - Pediatric AML (14:25-14:55)
- Patient: PAT-ODMND-0110
- Robot: COMPN-03 (Social Companion, Instance 3)
- Location: Pediatric Play Area 3
- Procedure: Pre-chemotherapy anxiety management and interactive play
- Duration: 30 minutes
- Anxiety score (pre-session): 7/10 (Wong-Baker FACES adaptation)
- Anxiety score (post-session): 3/10
- Interaction modalities: Storytelling, breathing exercises, drawing game
- Parent present: Yes (father)
- Outcome: Anxiety reduced. Patient ready for scheduled chemotherapy.

### Combined Imaging and Steerable Needle Ablation (14:30-14:58)
- Patient: PAT-ODMND-0111
- Robots: IMAGE-04 (Imaging Assistant, Instance 4) and STEER-01 (Steerable
  Needle, Instance 1)
- Location: Imaging Bay 4 (imaging phase), Ablation Suite 1 (ablation phase)
- Procedure: Robotic ultrasound liver assessment followed by CT-guided
  microwave ablation of 32 mm HCC lesion in segment VI
- Lenvatinib 12 mg administered orally at 14:28 per IND protocol (pre-ablation)
- Imaging phase (14:30-14:40): IMAGE-04 ultrasound with real-time tumor
  mapping. Probe pressure 1.9 N. Image quality 8.4/10. Tumor measured at
  32 x 26 mm. Scan coverage 94%.
- Ablation phase (14:42-14:58): STEER-01 CT-guided needle insertion to target.
  Needle tip placement accuracy 1.1 mm from planned trajectory. Microwave
  ablation at 60 W for 8 minutes. Ablation zone 42 x 38 mm (adequate margin).
  Real-time temperature monitoring confirmed target reached 65 degrees C.
- Outcome: Successful complete ablation. Post-ablation CT confirms adequate
  treatment zone with margins. Patient transferred to recovery.

### Needle Placement - Parotid Tumor (14:38-14:54)
- Patient: PAT-ODMND-0112
- Robot: NEEDLE-01 (Needle-Placement, Instance 1)
- Location: CT Suite 1
- Procedure: CT-guided fine needle aspiration of 18 mm right parotid mass
- Duration: 16 minutes (planning 4 min, insertion 8 min, sampling 4 min)
- Needle trajectory planned via AI: 45 mm depth, 22-degree angulation
- Needle tip accuracy: 0.8 mm from target center
- Passes completed: 3 of 3 planned
- Facial nerve proximity: 4.2 mm clearance (safety threshold 3 mm)
- Sample adequacy: Sufficient for cytology
- Outcome: Successful. No facial nerve compromise. Minimal discomfort.

### Humanoid Rehabilitation Support (14:42-14:56)
- Patient: PAT-ODMND-0113
- Robot: HUMAN-01 (Humanoid, Instance 1)
- Location: Humanoid Therapy Room 1
- Procedure: Post-surgical gait training and mobility assessment for
  13-year-old with left proximal tibial osteosarcoma (limb salvage, 4 weeks
  post-operative)
- Duration: 14 minutes (assessment 4 min, guided walking 8 min, cool-down
  2 min)
- Gait symmetry index: 0.72 (target greater than 0.85)
- Steps completed: 48
- Weight-bearing tolerance: 60% of body weight on affected limb
- Pain during session: 2/10 (acceptable)
- Outcome: Progress documented. Gait symmetry improving from 0.68 baseline.

### Diagnostic Imaging - Liver Metastases (14:48-14:59)
- Patient: PAT-ODMND-0114
- Robot: IMAGE-01 (Imaging Assistant, Instance 1)
- Location: Imaging Bay 1
- Procedure: Robotic ultrasound assessment of hepatic metastases from
  colorectal primary
- Duration: 11 minutes (ongoing at hour end)
- Probe pressure: 1.7 N average
- Image quality score: 7.9/10
- Lesions identified: 3 (segments II, V, VII)
- Largest lesion: 28 x 22 mm (segment V)
- Outcome: Scan continuing into Hour 15.

### Rehabilitation Exoskeleton Session (14:55-14:59)
- Patient: PAT-ODMND-0115
- Robot: REHAB-01 (Rehabilitation Exoskeleton, Instance 1)
- Location: Rehabilitation Bay 1
- Procedure: Lower-extremity exoskeleton-assisted gait training for 71-year-old
  with right femur osteosarcoma (post-endoprosthetic reconstruction, 6 weeks)
- Duration: Session initiated, continuing into Hour 15
- Initial assessment: Range of motion 0-85 degrees flexion (target 0-110)
- Exoskeleton fit confirmed, gait program loaded
- Outcome: Session in progress. Full report in Hour 15.

### Ongoing Procedure: PAT-ODMND-0097 Surgery
- Patient: PAT-ODMND-0097
- Robot: SURG-02 (Surgical Robot, Instance 2)
- Location: Surgical Suite 2
- Procedure: Ongoing robotic-assisted partial hepatectomy (started
  approximately 13:20)
- Status at 14:00: Parenchymal transection in progress
- Status at 14:30: Hemostasis and specimen extraction
- Status at 14:50: Closure and drain placement
- Estimated completion: 15:10
- Blood loss to 14:59: 340 mL (within acceptable range)

## Patient Departures This Hour

| Patient ID | Time | Outcome | Notes |
|-----------|------|---------|-------|
| PAT-ODMND-0107 | 14:35 | Discharged | RT fraction complete, no issues |
| PAT-ODMND-0108 | 14:48 | Discharged | Post-biopsy observation complete |

## Adverse Events

None this hour. All procedures completed or ongoing without reportable events.

## Investigational Drug Administrations

### Bevacizumab - PAT-ODMND-0109 (Glioblastoma)
- Drug: Bevacizumab 10 mg/kg IV
- IND Protocol: IND-2026-BEV-GBM-014
- Administration time: 14:20 (pre-RT)
- Route: Intravenous infusion over 30 minutes (started 13:50, completed 14:20)
- Lot number: BEV-2026-L0047
- Dispensed by: Pharmacy automated dispensing, verified by pharmacist RPh-D2
- Rationale: Anti-VEGF therapy per protocol to reduce tumor vascularity prior
  to stereotactic RT fraction per 21 CFR 312.23(a)(5)
- Adverse reactions: None observed during or after infusion
- Documentation: Case report form CRF-0109-BEV-003 completed per
  21 CFR 312.62

### Lenvatinib - PAT-ODMND-0111 (HCC)
- Drug: Lenvatinib 12 mg oral
- IND Protocol: IND-2026-LEN-HCC-009
- Administration time: 14:28 (pre-ablation)
- Route: Oral
- Lot number: LEN-2026-L0031
- Dispensed by: Pharmacy automated dispensing, verified by pharmacist RPh-D2
- Rationale: Multi-kinase inhibitor per protocol to enhance ablation response
  in Stage III HCC per 21 CFR 312.23(a)(5)
- Adverse reactions: None observed
- Documentation: Case report form CRF-0111-LEN-001 completed per
  21 CFR 312.62

## Site Utilization

- Overall robot utilization: approximately 52% (15 of 29 robots active at
  some point during the hour)
- Peak concurrent active robots: 10 (at 14:48)
- Queue lengths: 0 across all stations
- Average wait time: 6.2 minutes (range 5-8 minutes)
- Robot cleaning cycles: 4 (TRACK-02, COBOT-04, IMAGE-04, NEEDLE-01)
- Afternoon rehab sessions picking up with HUMAN-01 and REHAB-01 both active

## Regulatory Compliance Notes

### ICH E6(R3) - Adaption
- Section 1.1.1: All 9 new patient procedures conducted in accordance with
  ethical principles and applicable GCP requirements. Sustained high-volume
  operations maintained identical safety standards to lower-volume periods.
- Section 2.9.1: Complete audit trails maintained for all active procedures
  including beam-on times, dose delivery records, biopsy sample chain of
  custody, ablation temperature profiles, and needle placement coordinates.
- Section 2.10.1: No adverse events detected. Continuous safety monitoring
  across all 20 concurrent patients via centralized AI surveillance system.
- Section 4.2.1: Data capture for all procedures included synchronized UTC
  timestamps, robot telemetry at native sampling rates, and patient vital
  signs at 1-minute intervals during active procedures.
- Section 4.2.7: Investigational drug administration records for bevacizumab
  and lenvatinib archived with full lot traceability and pharmacist
  verification logs.

### 21 CFR Part 50 - Adaption
- Section 50.25: All 9 new patients had previously completed informed consent
  including Physical AI system disclosure, PSL readiness scores, and right to
  non-Physical AI alternatives.
- Section 50.25(a)(5): Bevacizumab and lenvatinib consent forms included
  specific IND drug risk disclosures, alternative treatment options, and
  Physical AI integration considerations.
- Subpart D (Sections 50.51-50.55): Pediatric protections applied for
  PAT-ODMND-0110 (7M, AML) and PAT-ODMND-0113 (13F, osteosarcoma). Parental
  assent obtained for both. IRB-approved pediatric protocols followed.
  Companion and humanoid robot interactions reviewed by pediatric oncology
  sub-investigator.

### 21 CFR Part 312 - Adaption
- Section 312.23: IND protocols for bevacizumab (GBM) and lenvatinib (HCC)
  maintained with complete investigational plans including Physical AI robot
  integration documentation.
- Section 312.32: Safety reporting systems active and monitoring all patients.
  No reportable events this hour. Two IND drug administrations completed
  without adverse reactions.
- Section 312.62: Investigator recordkeeping maintained for all patients
  including Physical AI system interaction logs, vital sign records, procedure
  documentation, and IND drug administration records with lot numbers and
  pharmacist verification.
- Section 312.68: Sponsor access to inspection-ready records confirmed for
  both IND protocols active this hour.

## Complementary Framework References

The Unification Standard Level (USL) framework (Kawchak, 2026;
DOI: 10.5281/zenodo.18778220) provides complementary robot technical
interoperability scoring. The sustained high-volume operations this hour
exercised 10 distinct robot instances across 8 of 10 robot types, validating
the multi-robot interoperability architecture that USL evaluates at the
platform level.

The single-patient cancer journey framework (Kawchak, 2026;
DOI: 10.5281/zenodo.19119939) demonstrated autonomous Physical AI trial
orchestration for an individual patient. PAT-ODMND-0111's combined
imaging-plus-ablation workflow with IND drug integration represents a
multi-robot, multi-modality treatment pathway within the on-demand context,
extending the journey framework to concurrent multi-patient operations.
